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The Parasitic Worm Product ES-62 Targets
Myeloid Differentiation Factor 88–Dependent
Effector Mechanisms to Suppress Antinuclear Antibody
Production and Proteinuria in MRL/lpr Mice
David T. Rodgers,1 Mairi A. McGrath,1 Miguel A. Pineda,1 Lamyaa Al-Riyami,2
Justyna Rzepecka,2 Felicity Lumb,2 William Harnett,2 and Margaret M. Harnett1
Objective. The hygiene hypothesis suggests that
parasitic helminths (worms) protect against the devel-
opment of autoimmune disease via a serendipitous side
effect of worm-derived immunomodulators that concom-
itantly promote parasite survival and limit host pathol-
ogy. The aim of this study was to investigate whether
ES-62, a phosphorylcholine-containing glycoprotein se-
creted by the filarial nematode Acanthocheilonema viteae,
protects against kidney damage in an MRL/lpr mouse
model of systemic lupus erythematosus (SLE).
Methods. MRL/lpr mice progressively produce
high levels of autoantibodies, and the resultant deposi-
tion of immune complexes drives kidney pathology. The
effects of ES-62 on disease progression were assessed by
measurement of proteinuria, assessment of kidney his-
tology, determination of antinuclear antibody (ANA)
production and cytokine levels, and flow cytometric
analysis of relevant cellular populations.
Results. ES-62 restored the disrupted balance
between effector and regulatory B cells in MRL/lpr mice
by inhibiting plasmablast differentiation, with a conse-
quent reduction in ANA production and deposition of
immune complexes and C3a in the kidneys. Moreover,
by reducing interleukin-22 production, ES-62 may de-
sensitize downstream effector mechanisms in the patho-
genesis of kidney disease. Highlighting the therapeutic
importance of resetting B cell responses, adoptive trans-
fer of purified splenic B cells from ES-62–treated MRL/
lpr mice mimicked the protection afforded by the hel-
minth product. Mechanistically, this reflects down-
regulation of myeloid differentiation factor 88
expression by B cells and also kidney cells, resulting in
inhibition of pathogenic cross-talk among Toll-like
receptor–, C3a-, and immune complex–mediated effec-
tor mechanisms.
Conclusion. This study provides the first demon-
stration of protection against kidney pathology by a
parasitic worm–derived immunomodulator in a model
of SLE and suggests therapeutic potential for drugs
based on the mechanism of action of ES-62.
Systemic lupus erythematosus (SLE) is character-
ized by high titers of autoantibodies, typically against
nuclear antigens. These autoantibodies generate im-
mune complex–mediated inflammation in the kidneys,
skin, joints, and cardiovascular system, with glomerulo-
nephritis being a major contributor to resultant morbid-
ity (1). Inflammation in the kidney is driven by cross-talk
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among immunoglobulin (Fc receptor [FcR]), comple-
ment, and Toll-like receptors (TLRs), resulting in the
production of cytokines and infiltration of proinflamma-
tory cells, which perpetuate chronic inflammation and
organ damage (1–3). Studies in interleukin-23 (IL-23)–
deficient mice suggest that the IL-23/IL-17 axis pro-
motes such kidney inflammation (4), and, perhaps re-
flecting this, expanded populations of Th17- and IL-17–
producing CD3CD4CD8 T cells are observed in
the kidneys of both lupus-prone mice and patients with
SLE (5). Moreover, IL-17 has been reported to act in
concert with BAFF to promote B cell survival and
(auto)antibody production (4–6). Consistent with the
central role of B cells in the pathogenesis of SLE,
increased expression of BAFF correlates with disease
activity in SLE, and overexpression of BAFF promotes
SLE-like pathology in mouse models, even in the ab-
sence of T cells. Specific targeting of this cytokine has
proved effective in suppressing pathology, in both mouse
models and human patients (3), and indeed, belimumab
(an anti-BAFF monoclonal antibody) is the first SLE-
specific treatment to be granted Food and Drug Admin-
istration approval in the past 50 years, although disap-
pointingly, disease activity was reduced only in a limited
number of patients during phase III trials (3,7).
Autoimmune inflammatory disorders appear to
be increasingly prevalent in the developed world. As
suggested by the hygiene hypothesis (8), this may reflect
reduced exposure to infection, particularly by parasitic
helminths (worms), which would normally shape and
balance immune responses to limit pathology and pro-
mote tissue repair (9,10). Consistent with this notion, in
experimental models of autoimmune disease, infection
with helminths was shown to be protective (9,10), and
this has generated interest in the potential for exploiting
worm-based immunomodulation for the treatment of
these inflammatory disorders in humans. Although clin-
ical trials involving infection with live parasites have
shown some promise in terms of therapeutic benefit to
patients with autoimmune inflammatory disease (11),
infection with pathogens is clearly not an ideal therapeu-
tic strategy; thus, much recent attention has focused on
the idea of developing novel drugs based on the individ-
ual helminth molecules (or their antiinflammatory tar-
gets) that promote parasite survival by limiting the
inflammatory response of the host in a safe manner (9).
In this study, we investigated whether ES-62, an immu-
nomodulator secreted by the filarial nematode Acantho-
cheilonema viteae (9), protects against pathology in the
MRL/lpr mouse model of SLE.
MATERIALS AND METHODS
Animal models. Animals were bred and/or maintained
in the Biological Services Units at the University of Glasgow
and the University of Strathclyde, in accordance with Home
Office UK Licences PIL60/9576, PIL60/11671, PIL60/12183,
PIL60/12950, PPL60/3580, PPL60/4492, PPL60/4300, and
PPL60/3810 and the ethics review boards of these universities.
Although lupus-like pathology develops in MRL/Mp mice
within 12–18 months, the Fas deficiency in the MRL/Mplpr/lpr
(MRL/lpr) strain accelerates disease, with these mice develop-
ing (within 4 months) high-titer antinuclear antibodies
(ANAs), glomerulonephritis, and arthritis-like footpad inflam-
mation as well as the splenomegaly/lymphadenopathy typical
of autoimmune lymphoproliferative syndrome (6,12).
Kidney damage, as evidenced by proteinuria, was
monitored twice weekly using Multistix (Siemens) and, where
indicated, arthritis was scored at the time of culling (13,14). In
addition, some mice were tested for renal function as evi-
denced by serum creatinine and blood urea nitrogen (BUN)
levels, using relevant detection kits (Arbor Assays KB02-H1
and K024-H1; Tebu-Bio). The mice were treated twice weekly
with phosphate buffered saline (PBS; 100 l subcutaneously
from 7 to 21 weeks of age), purified ES-62 (2 g in 100 l PBS
subcutaneously from 7 to 21 weeks of age) (15), mouse IgG
(Europa Bioproducts) (100 g in 100 l PBS intraperitoneally
from 7 to 21 weeks of age), or neutralizing anti–IL-22
(AM22.1; 100 g in 100 l PBS intraperitoneally from 12 to 21
weeks of age) (16) or anti–IL-17A (MM17F3; 100 g in 100 l
PBS intraperitoneally from 7 to 12 weeks of age) (17), mono-
clonal antibodies (kindly provided by Drs. Jean-Christophe
Renauld and Jacques Van Snick, Ludwig Institute for Cancer
Research, Belgium), or alternatively, with recombinant IL-22
(rIL-22; 1 g in 100 l PBS intraperitoneally from 12 to 21
weeks of age) or rIL-17A (PeproTech) (1 g in 100 l PBS
intraperitoneally from 12 to 21 weeks of age). ES-62 inhibited
proteinuria similarly in male and female MRL/lpr mice, and
proteinuria levels for MRL/lpr mice treated with PBS and
MRL/lpr mice treated with PBS plus IgG were not significantly
different. The absence of endotoxin from these reagents was
confirmed using an Endosafe Kit (Charles River) (15). Splenic
B cells obtained from ES-62– or PBS-treated MRL/lpr mice at
21 weeks were purified by negative selection using anti-CD43–
labeled magnetic beads (Miltenyi Biotec) (90%
B220CD3 B2 cells) and transferred into the tail vein of
recipient 7-week-old MRL/lpr mice (5  106 cells in 100 l
sterile PBS). Intravenously administered PBS (100 l) was
used as a control.
Ex vivo analysis. Blood samples were obtained by
cardiac puncture, and red blood cells were lysed prior to flow
cytometric analysis. Cells from the spleens or from popliteal,
inguinal, axial, and brachial lymph nodes (LNs; 106/ml) were
resuspended in RPMI medium containing 2 mM L-glutamine,
1 mM sodium pyruvate, 100 units/ml penicillin, 100 g/ml
streptomycin, and 1% nonessential amino acids (RPMI com-
plete medium) supplemented with 50 M 2-mercaptoethanol
and 10% heat-inactivated fetal calf serum (all from Invitro-
gen). Dissection of kidneys and generation of kidney superna-
tants enriched in interstitial fluid were performed as described
previously (18). Following red cell lysis, renal and hematopoi-
etic kidney cells were analyzed by flow cytometry using a gating
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strategy based on forward scatter versus side scatter exclusion
of dead cells/cell debris, exclusion of doublets, and selection of
live cells as discriminated using a Live/Dead Fixable Aqua
Dead Cell Stain kit (Invitrogen).
For analysis of intracellular cytokine production, cells
were incubated with medium or 50 ng/ml phorbol myristate
acetate (PMA) plus 500 ng/ml ionomycin (plus 10 g/ml
lipopolysaccharide [Escherichia coli O111:B4] for B cell re-
sponses) for 1 hour before the addition of 10 g/ml brefeldin
A (Sigma-Aldrich) for a further 5 hours at 37°C with 5% CO2
(13). Cells were stained with Live/Dead Fixable Aqua Dead
Cell Stain to allow exclusion of dead cells from the analysis
following permeabilization, using the solutions and protocols
provided by BioLegend. B cell populations (13) were analyzed
using the following phenotypic markers: Brilliant Violet 421–
conjugated anti-B220, phycoerythrin (PE)–conjugated anti-
CD138, Alexa Fluor 700– or PE–Cy7–conjugated anti-CD19;
PE-conjugated anti-CD1d; PE–Cy7–conjugated anti-CD23, PE–
Cy7–conjugated anti-CD43, PerCP–Cy5.5–conjugated anti-IgD,
allophycocyanin (APC)–Cy7–conjugated anti-IgM, APC-
conjugated anti-CD16/32, PerCP–Cy5.5–conjugated anti-CD80,
APC-conjugated anti-CD206 (all from BioLegend), and eFluor
450–conjugated anti-CD21 (eBioscience) (13).
For the identification of plasmablasts and plasma cells,
a dump channel (PerCP) identifying CD11c, CD11b, CD4,
CD8, F4/80, and Gr-1 (and CD3, when indicated) markers was
used to facilitate exclusion of non-B CD138 cells (13).
Intracellular analysis involved staining with APC-conjugated
anti–IL-6, APC-conjugated anti–IL-10 (BioLegend) (13), or
anti-myeloid differentiation factor 88 (anti-MyD88) (Abcam)
and fluorescein isothiocyanate (FITC)–conjugated goat anti-
rabbit IgG (Vector) (14). Data were acquired using BD
FACSCalibur and BD LSR II flow cytometers (BD Biosci-
ences) and analyzed using FlowJo software (Tree Star) (13).
MyD88 expression in the kidney (30 g/sample) was addition-
ally assessed by Western blotting using anti-MyD88 (ab2068;
Abcam) and densitometric analysis using ImageJ software
(National Institutes of Health) (14).
The levels of cytokines (IL-17A [BioLegend], IL-17E
and IL-17F [eBioscience], and IL-22 [R&D Systems]) in serum
and kidney supernatants were analyzed by enzyme-linked
immunosorbent assay (14,19). ANAs were visualized using
HEp-2 slides (Antibodies Inc.) and FITC-conjugated anti-
mouse IgG (Vector). Quantitative analysis was performed by
determining the end point dilutions of serum from individual
mice (102–105 log dilutions); the final dilution at which intra-
cellular fluorescence was detectable was recorded. ANA reac-
tivity was visualized using an Axiovert S100 fluorescence
microscope (Zeiss).
Kidney pathology. Kidneys were fixed in formalin (24
hours at 4°C), treated with 30% sucrose (24 hours at 4°C),
embedded in Tissue-Tek OCT medium, and snap-frozen in
liquid nitrogen. Sections (7 m) were stained with Harris’
hematoxylin and eosin (Sigma-Aldrich) and imaged using an
Olympus BX41 camera with Cell software. Hypercellularity
was assessed by analyzing 20 glomerular cross-sections per
kidney. Deposition of C3a and IgG was detected using rat
anti-mouse C3 (11H9: Abcam)/Alexa Fluor 647–conjugated
goat anti-rat IgG (Invitrogen) or rabbit anti-mouse IgG (The
Jackson Laboratory)/Alexa Fluor 488–conjugated goat anti-
rabbit IgG (Invitrogen), respectively, and visualized using an
EVOS fluorescence microscope (Life Technologies). Differ-
ences between PBS- and ES-62–treated groups were detected
using 1:10 and 1:25 dilutions (but not dilutions of1:50) of the
primary antibodies.
Statistical analysis. Proteinuria data were analyzed by
two-way analysis of variance with the Bonferroni post hoc test,
and experimental data were analyzed by Student’s t-test. Non-
parametric data were analyzed using the Mann-Whitney test.
RESULTS
Suppression of proteinuria in MRL/lpr mice by
ES-62. Proteinuria, a surrogate for glomerular vascular
permeability, inflammation, and kidney damage, was
detected in MRL/lpr mice, but not in MRL/Mp mice, by
16 weeks of age and increased thereafter, indicating that
progressive kidney damage was occurring (Figure 1A).
Treatment of the MRL/lpr mice with ES-62 reduced the
level of proteinuria (Figure 1A) and the associated
incidence of disease (3 mg/ml protein: 0% in MRL/Mp
mice, 100% in PBS-treated MRL/lpr mice, and 22.2% in
ES-62–treated MRL/lpr mice). Moreover, additional
parameters of renal function were also tested in some
mice (proteinuria at 21 weeks: 20 mg/ml in all PBS-
treated mice and mean  SEM 0.98  0.36 mg/ml in
ES-62–treated mice), and this showed that ES-62 re-
duced serum creatinine levels both prior to and during
established proteinuria (12 weeks and 21 weeks, respec-
tively), although at 21 weeks, the reduction did not reach
significance (Figure 1A).
In contrast, ES-62 did not significantly reduce
BUN levels (data not shown), but this presumably
reflected that these levels were still in the normal range
(35 mg/dl), because typically these levels do not be-
come elevated in MRL/lpr mice until 24–32 weeks of
age (20–22). However, both the severity of arthritis
(Figure 1A) and the incidence of arthritis (72.7% in the
PBS-treated mice and 8.3% in the ES-62–treated mice)
were suppressed in the ES-62–treated MRL/lpr mice
examined. Moreover, although systematic survival ana-
lysis was precluded due to ethical constraints, exposure
to ES-62 promoted the survival of MRL/lpr mice (66.7%
of PBS-treated mice and 92.9% of ES-62–treated mice)
over the 21-week time course of the experiments.
ES-62–induced suppression of ANA production
in MRL/lpr mice. ES-62 did not significantly modulate
the levels of total IgG1, IgG2a, or IgM in the serum of
MRL/lpr mice (data not shown). In contrast, ES-62
inhibited the production of ANAs, as measured in the
serum of MRL/lpr mice, both prior to (12 weeks; data
not shown) and during established disease (21 weeks).
Similarly, the levels of ANA weakly detected in the
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Figure 1. ES-62 suppresses proteinuria and antinuclear antibody (ANA) production in MRL/lpr mice. A, Proteinuria was measured twice weekly
in male MRL/Mp mice (n  15) and MRL/lpr mice treated with either phosphate buffered saline (PBS) (n  16) or ES-62 (n  19), administered
subcutaneously twice weekly from 7 to 21 weeks of age. Serum creatinine levels and arthritis articular scores were also determined in some of the
individual MRL/lpr mice treated with PBS or ES-62 examined for these disease parameters. B, Left, Immunofluorescence imaging of HEp-2 cell staining
by ANAs in the serum of PBS-treated and ES-62treated MRL/lpr mice. Original magnification  63. Middle, ANA levels in the serum of individual
PBS-treated (n 6) and ES-62treated (n 6) MRL/lpr mice, as measured by end point dilution analysis. Right, Immunofluorescence imaging showing
weak detection of ANAs in kidney supernatant (KS) at a dilution of 102. Original magnification  63. C, Proportions of plasmablast-like
CD138B220lowCD19B cells in the kidneys at 12 and 21 weeks (first and second panels), CD138B220CD19 plasma cells in the kidneys at 12 weeks
(third panel), and plasmablasts and plasma cells in blood at 12 weeks in mice treated with PBS or ES-62 (fourth and fifth panels). Samples from the relevant
treatment groups were pooled. In the fourth and fifth panels, values in the gates are the percentage of DumpCD138 cells; values in the boxes are the
percentage of live cells. D, Levels of interleukin-17A (IL-17A) and BAFF in serum (first and second panels, respectively), levels of IL-17A in kidney
supernatant (third panel) at the time of culling, as measured by enzyme-linked immunosorbent assay, and proteinuria (fourth panel) in MRL/lpr mice.
Proteinuria was measured twice weekly in mice that received twice-weekly intraperitoneal injections of mouse IgG (100 g in 100 l PBS from 7 to 21
weeks, n 16) or anti–IL-17A (100 g in 100 l PBS from 7 to 12 weeks, n 8) or recombinant IL-17A (rIL-17A; 1 g in 100 l PBS from 12 to 21 weeks,
n  6). Values for proteinuria are the mean  SEM and in A are collated from 3 independent experiments. In A (second and third panels), B (middle
panel), C (first, second, and third panels), and D (first, second, and third panels), each symbol represents an individual mouse; bars show the mean.  
P 0.05;  P 0.01;  P 0.001. Black asterisks indicate PBS-treated MRL/lpr mice versus MRL/Mp mice. Blue asterisks indicate PBS-treated
versus ES-62–treated MRL/lpr mice or rIL-17A–treated versus murine IgG–treated mice.
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kidney supernatants were also reduced following expo-
sure to ES-62 (Figure 1B). Consistent with this suppres-
sion of pathogenic autoantibody production, the num-
bers (data not shown) and proportions of the
plasmablast-like CD138B220lowCD19 B cells that
may represent short-lived plasma cells (13) were re-
duced in the kidneys of mice exposed to ES-62, at both
12 weeks and 21 weeks (Figure 1C). These cells are
associated with disease flares in patients with SLE and
are the likely source of pathogenic anti–double-stranded
DNA (anti-dsDNA) IgG2a and IgG3 autoantibodies
(23). In contrast, the percentage of long-lived
CD138B220CD19 plasma cells (13), which have
been reported to be responsible for producing anti-RNA
and anticardiolipin antibodies (23), was reduced in the
kidneys prior to (Figure 1C) but not during established
disease (mean  SEM 1.8  0.6% in PBS-treated mice
and 2.4  0.6% in ES-62–treated mice). At 21 weeks,
however, the proportions of both plasmablasts and
plasma cells were reduced in the blood of ES-62–treated
mice relative to PBS-treated mice (Figure 1C).
Association between ES-62–induced suppression
of B cell responses in MRL/lpr mice and resetting the
balance between effector and regulatory B cells. To
address the mechanisms underpinning the suppression
of ANA production and the reduced levels of
CD138B220lowCD19 plasmablast-like B cells, we
first investigated the effect of in vivo exposure to ES-62
on BAFF and IL-17 expression, because these cytokines
have been proposed to synergize and promote (auto)an-
tibody production (4,5). This investigation revealed that
ES-62 did not suppress the levels of either cytokine in
the serum or kidney supernatants of MRL/lpr mice
(mean  SEM BAFF levels in kidney supernatants
4,823  333 pg/ml in PBS-treated mice and 5,084 
1,543 pg/ml in ES-62–treated mice) (Figure 1D), nor did
the parasite product decrease the levels in kidney super-
natants of IL-17E (mean  SEM 949  127 pg/ml in
PBS-treated mice and 1,067  153 pg/ml in ES-62–
treated mice) or IL-17F (333  61 pg/ml in PBS-treated
mice and 433  104 pg/ml in ES-62–treated mice), the
latter of which was recently correlated with disease
activity in SLE (24). Moreover, neutralizing anti–IL-17
antibodies did not block ANA production (data not
shown) or development of proteinuria (Figure 1D).
Indeed, ES-62 tended to promote IL-17 production in
the kidney during established proteinuria, and consistent
with this, administration of rIL-17 from 12 weeks on-
Figure 2. ES-62 modulates effector B cells by targeting myeloid differentiation factor 88 (MyD88). A, Total numbers of splenic follicular 1 (Fo1)
B cells (CD19CD93CD21intermediateCD23IgDhighIgMlow) in individual 21-week-old PBS- and ES-62–treated MRL/lpr mice, as determined by
flow cytometry. B, Expression of CD80 (first and second panels) and Fc receptor IIb (FcRIIb) (third and fourth panels) on CD19 splenic B cells
from PBS- and ES-62–treated MRL/lpr mice. C, Expression of IL-6–producing splenic B cells from MRL/lpr mice following in vivo exposure to PBS
or ES-62. D, Intracellular levels of MyD88 in CD19 and Dump–CD3–CD138 B cells from PBS- and ES-62–treated MRL/lpr mice. In A (first
panel), B (second and fourth panels), C (second panel), and D (middle panel), each symbol represents an individual mouse; bars show the mean.
  P  0.05. MFI  mean fluorescence intensity (see Figure 1 for other definitions).
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ward partially suppressed proteinuria (incidence 40%)
(Figure 1D).
Mice treated with ES-62 displayed increased total
numbers of splenic CD19 B cells (mean  SEM
61.5  7.5  106 in PBS-treated mice [n  11] and 90.02
 9.2  106 in ES-62–treated mice [n  18])
and follicular 1 B cells (CD19CD93CD21intermediate
CD23IgDhighIgMlow) (Figure 2A) but not T cells (re-
sults not shown), perhaps suggesting that the reduced
plasmablast differentiation reflected induction of a hy-
poresponsive phenotype of B cells. Consistent with this,
expression of CD80 on splenic B cells was down-
regulated, while that of Fc receptor IIb was up-
regulated (Figure 2B) in ES-62–treated MRL/lpr mice.
Furthermore, following ex vivo stimulation, the levels of
IL-6–producing splenic B cells, which are proposed to be
an important driver of autoimmunity in mice (25), were
reduced by in vivo exposure to ES-62 (Figure 2C). This
was reflected by a reduction in the IL-6 messenger RNA
levels (mean SEM relative quantity value 0.67 0.13)
observed in splenic CD19CD3 B cells purified from
ES-62–treated MRL/lpr mice when normalized to those
from PBS-treated mice.
Similarly, such purified splenic B cells from ES-
62–treated mice produced less interferon- than those
from PBS-treated control mice (mean SEM 284 104
versus 540  51 pg/ml) in ex vivo cultures. However,
surface expression of IgD and IgM was not modulated
(data not shown); thus, ES-62 does not simply induce
anergy resulting from down-regulation of the B cell
receptor. Intriguingly, given the abrogation of ANA
responses reported in MRL/lpr mice with MyD88-
deficient B cells (26), B cells, including CD138 B cells
(Figure 2D) from ES-62–treated MRL/lpr mice, exhib-
ited reduced levels of MyD88.
In contrast, the levels of B cells with the capacity
to produce IL-10, particularly CD19CD21CD23
B cells analogous to those proposed to exhibit regulatory
function in MRL/lpr mice and SLE (27,28), were in-
creased in the spleen and kidney in ES-62–treated mice
(Figure 3A). Moreover, the levels of CD19CD21
CD23 B cells were increased in the blood of ES-62–
treated mice (Figure 3B). Such “regulatory” B cells have
been reported to mediate their protective effects, at least
in part, via the induction of Treg cells, particularly
IL-10–producing CD4 T (Tr1) cells, in MRL/lpr mice
(27,28). Consistent with the proposed protective role of
Treg cells in SLE (29), the proportion of FoxP3CD4
Treg cells and IL-10CD4Tr1 cells in the LNs of
MRL/lpr, but not MRL/Mp, mice declined with age
(although the absolute numbers increased), with kinetics
that correlated with the initiation and progression of
Figure 3. ES-62 induces IL-10–producing B cells but not T cells. A, IL-10 production by spleen and kidney cells from PBS- and ES-62–treated
21-week-old MRL/lpr mice stimulated ex vivo, as determined by flow cytometry. B, Proportions of CD19CD21CD23 B cells in the blood of
PBS- and ES-62–treated MRL/lpr mice at 21 weeks. C, Proportions of FoxP3 Treg cells (left) and IL-10 Tr1 cells (right) in the lymph nodes (LNs)
of MRL/Mp mice (n 3), ES-62–treated MRL/lpr mice (n 3–5), and PBS-treated MRL/lpr mice (n 5) at all time points. Values are the mean
SEM. D, Levels of Treg cells and Tr1 cells in the kidneys of MRL/lpr mice at 21 weeks. In A (third and fourth panels) and D, each symbol represents
an individual mouse; bars show the mean.   P  0.05. See Figure 1 for other definitions.
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proteinuria. Treatment with ES-62, however, did not
increase the levels of Treg or Tr1 cells in the LNs
(Figure 3C), spleens (data not shown), or kidneys (Fig-
ure 3D) of MRL/lpr mice.
ES-62–induced protection against kidney dam-
age correlates with antagonism of IL-22 responses and
is mimicked by transfer of B cells from ES-62–treated
MRL/lpr mice. Perhaps surprisingly, given the striking
inhibition of proteinuria, histologic analysis of kidneys
from ES-62–treated MRL/lpr mice (Figure 4A) did not
reveal any substantial modulation of glomerular hyper-
cellularity, as confirmed by counting cells within individ-
ual glomeruli (mean  SEM 63.6  4.8 in PBS-treated
mice [n 26] and 64.4 7.4 in ES-62–treated mice [n
18]). Exposure to ES-62 did, however, reduce IgG and
C3 deposition in the kidneys (Figure 4B) and modulated
the phenotype of the infiltrating cell population, selec-
tively reducing the proportion of CD3 T cells, Lin
CD127 innate lymphoid cells (ILCs), and CD11b
cells (Figure 4C) while increasing the levels of antiin-
flammatory F4/80highCD11cCD206Ly-6G M2
macrophages (Figure 4D) (mean  SEM 2  0.4% of
live cells in PBS-treated mice and 5.5 2.5% of live cells
in ES-62–treated mice) associated with protection,
which appear to be depleted in SLE (30).
The cytokine IL-22, which can promote barrier
integrity and wound repair (31), was recently reported to
stimulate kidney regeneration after acute injury by act-
ing on tubular epithelial cells (32). In the current study,
however, ES-62 suppressed the levels of IL-22 in kidney
supernatants (Figure 5A). Thus, as IL-23 promotes
IL-22 responses, and because of the increasing recogni-
tion of pathogenic roles for IL-22 in autoimmune disor-
ders (33,34) including SLE (35–38), we investigated
Figure 4. ES-62 modulates cellular infiltration and deposition of IgG and C3 in the kidney. A, Glomerular hypercellularity (top) and cellular
infiltration (bottom) in hematoxylin and eosinstained kidney sections from 21-week-old MRL/Mp and MRL/lpr mice treated with PBS or ES-62.
Original magnification  40 (top);  10 (bottom). B, Deposition of IgG and C3 in the kidneys of MRL/lpr mice treated with PBS or ES-62, as
detected using rabbit anti-mouse IgG/Alexa Fluor 488conjugated goat anti-rabbit IgG and rat anti-mouse C3/Alexa Fluor 647conjugated goat
anti-rat IgG, respectively. Original magnification  40. C, Proportions of CD3 T cells, LinCD127 innate lymphoid cells, and CD11b cells in
the kidneys of MRL/lpr mice treated with PBS or ES-62. Each symbol represents an individual mouse; bars show the mean. D, Levels of
CD206Ly-6G M2 macrophages in the kidneys of MRL/lpr mice treated with PBS or ES-62. The values shown represent the percentage of cells
in the CD206Ly-6G gate; when indicated, however, these were further analyzed as F4/80CD11c cells as a proportion of live cells.   P 
0.05. See Figure 1 for definitions.
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Figure 5. ES-62 suppresses pathogenic IL-22 production and myeloid differentiation factor 88 (MyD88) expression in the kidney. A, IL-22 levels
in kidney supernatant derived from PBS- and ES-62treated MRL/lpr mice, as measured by enzyme-linked immunosorbent assay. B, Left,
Proteinuria in MRL/lpr mice that received twice-weekly intraperitoneal injections of rIL-22 (1 g in 100 l PBS from 12 to 21 weeks of age, n 
10), antiIL-22 (100 g in 100 l PBS from 12 to 21 weeks of age, n  9), or mouse IgG (100 g in 100 l PBS from 7 to 21 weeks of age, n 
16). The IgG data are the same as those shown in Figure 1D, as the matched IL-17 and IL-22modulated groups were analyzed in parallel cohorts
to promote the 3 Rs (replace, reduce, refine). Right, Glomerular hypercellularity in hematoxylin and eosin (H&E)stained kidney sections (top)
and ANA production in serum (102 dilution) (bottom) from MRL/lpr mice treated with PBS or antiIL-22. Original magnification  40 (top);
 63 (bottom). C, Left, MyD88 expression in kidney cells from MRL/Mp and MRL/lpr mice at 12 weeks of age (top) and from PBS- and
ES-62treated MRL/lpr mice at 21 weeks of age (bottom), as determined by flow cytometric analysis. Middle, MyD88 expression in the kidneys of
individual PBS- or ES-62treated MRL/lpr mice. Right, Western blots showing MyD88 levels in kidney protein lysates derived from MRL/lpr mice
treated with IgG, antiIL-22, or rIL-22 (top), and densitometric analysis of MyD88/-actin expression, normalized to IgG control (bottom).
D, Proteinuria (left), glomerular hypercellularity and ANA production (middle), and IL-22 expression (right) in recipient MRL/lpr mice in which
splenic B cells harvested from MRL/lpr mice were transferred. Purified splenic CD43 B cells from 21-week-old MRL/lpr mice treated with ES-62
(n  4) or PBS (n  4) were transferred (5  106 cells pooled in 100 l sterile PBS) into the tail veins of 7-week-old MRL/lpr mice; intravenous
(IV) PBS was used as a control. Proteinuria in the recipient mice (6 received PBS, 8 received PBS-treated B cells, and 8 received B cells from
ES-62–treated mice) was measured twice weekly. Kidney sections were stained with H&E for analysis of glomerular hypercellularity, and serum analyzed
for ANA production. IL-22 was measured in the kidneys of mice from one of these experiments. Values for proteinuria are the mean SEM (n number
of relevant individual mice pooled from 2 independent experiments). In A, C (middle), and D (right), each symbol represents an individual mouse; bars
show the mean.   P  0.05;   P  0.01;   P  0.001. MFI  mean fluorescence intensity (see Figure 1 for other definitions).
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whether IL-22 production in the kidney was associated
with SLE pathogenesis. Administration of rIL-22 signif-
icantly accelerated and exacerbated the development of
proteinuria. In contrast, neutralization of this cytokine
suppressed proteinuria, although treatment with anti–
IL-22 did not prevent glomerular hypercellularity or
ANA production (Figure 5B). Exposure of MRL/lpr
mice to ES-62 plus anti–IL-22 resulted in no significant
differences between this combination treatment and
protocols with either anti–IL-22 or ES-62 plus IgG alone
(data not shown). Instead, although expression of
MyD88 was up-regulated in kidney cells from MRL/lpr
mice relative to MRL/Mp mice, it was reduced in kidney
cells from ES-62–treated MRL/lpr mice and anti–IL-22–
treated MRL/lpr mice, and rIL-22 appeared to maintain
(if not substantially increase) MyD88 levels (Figure 5C).
Collectively, these data are consistent with the notion
that IL-22 plays a pathogenic role in promoting MyD88-
dependent inflammation and vascular barrier permea-
bility in the MRL/lpr mouse and suggest that this
cytokine activity may be targeted by ES-62 to mediate
some of its protective effects in the kidney.
Finally, in order to confirm that the protection
against proteinuria afforded by the helminth product
was attributable to ES-62 resetting effector B cell re-
sponses, we investigated the effect of adoptively trans-
ferring purified splenic B cells harvested from MRL/lpr
mice treated with either PBS or ES-62 into recipient
7-week-old MRL/lpr mice. Strikingly, the transfer of B
cells from ES-62–treated MRL/lpr mice was sufficient to
provide significant protection against the development
of proteinuria in the recipient mice despite, as was
observed with ES-62, no substantial improvement in
glomerular hypercellularity (Figure 5D). However,
transfer of B cells from ES-62–treated mice did suppress
pathogenic ANA production (Figure 5D) (mean SEM
reciprocal end point dilutions 68,500  19,956 in mice
treated with intravenous PBS, 55,000  25,981 in mice
that received B cells from MRL/lpr mice treated with
PBS, and 5,500  5,196 in mice that received B cells
from MRL/lpr mice treated with ES-62) and reduced
IL-22 levels in kidney supernatants (Figure 5D), indicat-
ing that modulation of IL-22 responses is secondary to
ES-62–mediated resetting of the balance between effec-
tor and regulatory B cells.
DISCUSSION
ES-62 significantly suppresses pathogenic ANA
production (but not total IgG or IgM production) and
consequent deposition of IgG and C3a in the kidneys of
MRL/lpr mice. In addition, ES-62 reduces IL-22 levels
and modulates the phenotype of the kidney cellular
infiltrate, effects that collectively result in suppressed
development of proteinuria (Figure 6), a biomarker of
the kidney inflammation and damage that are the major
causes of mortality in the MRL/lpr mouse model of SLE
(12). ES-62 appears to prevent ANA generation by
down-regulating the expression of B cell MyD88; the
notion that this homeostatic regulation of effector B cell
responsiveness by the helminth product is relevant to the
observed protection is validated by studies in which
purified splenic B cells from ES-62–treated MRL/lpr
mice similarly suppress ANA production and also devel-
opment of proteinuria in recipient MRL/lpr mice. More-
over, and consistent with our findings, studies by other
investigators using the MRL/lpr (26) and Lyn/ (39)
mouse models of SLE have shown that complete dele-
Figure 6. Schematic representation of the action of ES-62. ES-62
desensitizes hyperresponsive B cells in MRL/lpr mice, resulting in a
lower level of plasmablasts and, consequently, suppression of antinu-
clear antibody (ANA) production and IgG and C3a deposition in the
kidney. This population of hyporesponsive effector B cells has a higher
frequency of B cells that can potentially reset the balance between
effector cells and regulatory cells via the production of interleukin-10
(IL-10) and/or other regulatory B (Breg) cell mechanisms. In addition
to reducing the levels of pathogenic ANAs, this hyporesponsive
phenotype is associated with a reduction in pathogenic IL-22 responses
in the kidney, which is reflected, at least in part, by down-regulation of
myeloid differentiation factor 88 (MyD88) expression in kidney cells.
ES-62 may also act directly to down-regulate MyD88 in kidney cells
and in this way act to desensitize the pathogenic cross-talk among
Toll-like receptors, Fc receptors, and complement receptors that
results in glomerular vascular permeability, inflammation, and kidney
damage.
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tion of MyD88 in B cells is sufficient to abrogate ANA
production (but not that of total IgG), proteinuria, and
glomerulonephritis, and as with ES-62, reduces the
number of plasmablasts while increasing the numbers of
follicular and total splenic B cells.
The IL-23/IL-17A axis has been proposed to play
a pathogenic role in SLE (4,5), but ES-62 did not
suppress IL-17 production, and neutralizing antibodies
to this cytokine did not abrogate disease progression.
Although anti–IL-17 treatment has been shown to sup-
press the levels of anti-dsDNA antibodies and protein-
uria in the MRL/lpr mouse model, this occurred during
the initiation phase (12 weeks) (6), and, consistent
with our observations that the number of plasma cells
decreased at this stage, ES-62 suppressed the levels of
IL-17A–producing CD4 and / T cells in LNs at 9
weeks (data not shown). Moreover, although levels of
IL-17A have been widely shown to be elevated in
patients with SLE, only a few studies have shown that
IL-17A levels correlate with the SLE Disease Activity
Index (SLEDAI) (40–48), with slightly more studies
concluding either that IL-17A levels do not correlate
with the SLEDAI or that these levels are actually
inversely correlated with the disease score (49–60).
Of note, IL-23 can also promote IL-22 responses
(61), a finding that perhaps reconciles some of these
contradictory data relating to the role of the inflamma-
tory IL-23/IL-17 axis in SLE. Pertinently, we observed
that IL-17 and IL-22 are produced by distinct popula-
tions of cells in the MRL/lpr mouse, with typically at the
time of culling only 1–2% of IL-22 cells in LNs
producing IL-17 in response to ex vivo stimulation with
PMA/ionomycin. Moreover, although exposure to ES-62
results in significantly lower levels of IL-22 but not
IL-17 CD3B220CD4CD8 (double-negative) T
cells, it induces higher levels of IL-17 but not IL-22
ILCs, suggesting that targeting of particular cellular
sources of IL-17 and IL-22 allows ES-62 to modulate the
distinct, potentially counterregulatory, effector func-
tions of these cytokines in the MRL/lpr mouse (data not
shown).
Thus, while not ruling out the possibility that
IL-17A may promote initiation of pathogenesis, our data
clearly suggest that this cytokine can resolve inflamma-
tion during established disease, a hypothesis that is
consistent with the proposed dual roles of IL-17 in
initiating and resolving kidney disease in experimental
crescentic glomerulonephritis (62). In contrast, and con-
sistent with its role in linking the regulation of inflam-
matory responses and barrier tissue homeostasis (31,34),
IL-22 appears to promote pathogenic effector cell mech-
anisms in the kidney. Thus, although a disease-causing
role for IL-22 has yet to be established unequivocally in
SLE, our data resonate with reports that this cytokine is
associated with pathogenesis (36,37) and may be predic-
tive of specific pathologies in certain patients with SLE
(35).
Although deletion of MyD88 signaling in B cells
is sufficient to abrogate lupus nephritis in the MRL/lpr
and Lyn/ mouse models (26,39), MyD88 deficiency in
dendritic cells (DCs) can also confer some protection
and highlights the cooperation between B cells and DCs
(26,63), and potentially other (nonhematopoietic) cells,
in the development of SLE-like pathologies. Interest-
ingly, therefore, MyD88-dependent cooperation be-
tween myeloid and endothelial cells was recently proven
to be key to the promotion of the vascular inflammation
and atherosclerosis associated with metabolic syndrome
(64). Thus, because MyD88 is likely to be a key player in
integrating cross-talk among TLR, FcR, and comple-
ment receptors, in concert with the reduction in IgG and
C3a deposition, our finding that ES-62 and anti–IL-22
down-regulate MyD88 expression in kidney cells pro-
vides an effective mechanism for protecting against
kidney inflammation. In addition, and relating to the
IL-22–mediated regulation of barrier function and vas-
cular inflammation alluded to above, IL-1 was recently
shown to act on endothelial cells to stimulate an NF-
B–independent, MyD88/ADP ribosylation factor
(ARF) nucleotide binding site opener (ARNO)/ARF
6–dependent pathway of vascular permeability that con-
tributes to vasculitis in autoimmune disease (65). There-
fore, disruption of the cooperative interplay resulting
from partial down-regulation of MyD88 signaling in B
cells and kidney cells would act to break the persistent
cycle of inflammation and vascular permeability result-
ing in kidney damage in SLE without fully immunosup-
pressing the host.
The ability of ES-62 to suppress pathogenic B cell
and effector cell responses appears to be associated with
a homeostatic resetting of the effector cell–to–
regulatory cell balance, as indicated by the reduction in
the frequency of pathogenic plasmablasts and the in-
creased number of CD19CD23CD21 B cells with
the capacity to produce IL-10, a phenotype reminiscent
of the regulatory B cells proposed to be defective in
MRL/lpr mice (28) and SLE (27). Interestingly, there is
increasing evidence that the dampening of inflammatory
responses by some helminth products may reflect, at
least in part, activation of regulatory B (“Breg”) cell
function (66,67). Indeed, patients with multiple sclerosis
who have helminthic infection exhibit less severe dis-
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ease, and such protection appears to be associated with
elevated levels of IL-10–producing B cells (68). More-
over, in a mouse model of asthma, IL-10–producing B
cells induced by the trematode helminth Schistosoma
mansoni suppressed disease (69,70), and in addition, B
cells from mice infected with the gastrointestinal nema-
tode Heligmosomoides polygyrus protected against the
development of both allergic airway inflammation and
autoimmune inflammation in an experimental model of
autoimmune encephalomyelitis (71). Nevertheless, re-
cent genetic studies suggest that regulatory B cells do
not counterregulate pathogenic effector B cell responses
in the MRL/lpr mouse in an IL-10–dependent manner
(72), and although these data may reflect their dysfunc-
tional phenotype and loss in this mouse strain, our
preliminary in vitro data also suggest that while B cells
from ES-62–treated MRL/lpr mice inhibit T cell re-
sponses, they may do so in an IL-10–independent man-
ner.
These findings reflect the increasing recognition
that regulatory B cells can exploit a variety of mecha-
nisms to limit chronic inflammation (73), and in any
case, expanded populations of such regulatory B cells
can transfer protection in MRL/lpr mice (27,28), sug-
gesting that regardless of their mode of action, they
could be exploited therapeutically. To date, however,
therapies aimed at targeting effector B cells and/or
resetting the balance between effector and regulatory
cells have been disappointing in clinical trials in SLE;
therefore, the need remains for the development of new
and safer therapies to achieve this. Thus, exploiting the
targets identified by parasitic helminths, which appear to
have evolved such homeostatic actions as regulating
proinflammatory MyD88 signaling in several cell types
including B cells, as a general and safe mechanism to
dampen hyperinflammatory responses may provide an
alternative blueprint for the development of novel bio-
logic agents or drugs to treat SLE.
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